drugset / Trial / NCT02513147

HIV Reservoir Dynamics After Switching to Dolutegravir in Patients on a PI and 2 NRTI Based Regimen

NCT02513147

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess changes in viral reservoir after changing IP/r to dolutegravir in HIV-1 infected patients maintaining undetectable viral load on Antiretroviral Therapy (ART).

Timeline

Start
2015-06
Primary completion
2016-11
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Atazanavir Other / unclassified 400 mg
Subject Darunavir Small molecule
Subject Dolutegravir Other / unclassified 50 mg
Subject Fosamprenavir Small molecule
Subject Lopinavir Other / unclassified
Background Ritonavir Other / unclassified 100 mg

Indications

No indication recorded.